pegozafermin (BIO89-100) - 89Bio
https://www.aasld.org/the-liver-meeting/fibrosis-improvement-pegozafermin-treatment-mash-patients-f4-fibrosis-analysis-24
 
Rohit Loomba1; Arun Sanyal2; Kris V. Kowdley3; Deepak L Bhatt4; Naim Alkhouri5; Juan Pablo Frias6; Pierre Bedossa7; Stephen Harrison8; Donald J. Lazas9; Robert Barish10; Mildred Gottwald11; Shibao Feng11; Germaine D. Agollah11; Leo Tseng11; Cynthia Hartsfield11; Hank Mansbach11; Maya Margalit11; Manal F. Abdelmalek12; 1University of California, San Diego, San Diego, CA; 2Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University, Richmond, VA; 3Swedish Medical Center, Seattle, WA; 4Icahn School of Medicine at Mount Sinai Health System; 5Arizona Liver Health, Phoenix, AZ; 6Velocity Clinical Research; 7Newcastle University; 8Relypsa Inc; 9Digestive Health Research; 10 Ocala GI Research; 1189bio, CA; 12Mayo Clinic, Rochester, MN
 
Oct 12, 2023
 
Prev Next